Company intelligence / Profile preview
Orexa
Herpen, Netherlandsorexa.eu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Orexa has completed preclinical research and a successful Phase 1 trial showing strong signals. The current focus is on testing efficacy in patients during multiple ongoing or planned Phase 2 trials targeting increased food intake to improve health outcomes and reduce hospital stays. The lead compound is an oral proprietary formulation designed to increase food intake, based on a well-known anesthetic agent. The first patient was dosed in January/February of 2024 for the postoperative ileus trial.
- Therapeutic areas
- GastroenterologyPsychiatryMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Orexa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orexa.